Skip Navigation Archive: U.S. Department of Health and Human Services U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality
Archival print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

  • Publication # 13-RA004

The March 2014 issue of Research Activities was the last issue of the monthly newsletter. AHRQ is transitioning to a new quarterly thematic publication that will provide longer, more in-depth analyses of individual topics related to AHRQ’s four priority areas. This new publication will be available online  in the Fall.

Research Activities readers will still be able to access published studies by AHRQ and AHRQ-supported researchers on the AHRQ Research Studies Web page, which will be online later this Spring. Studies can be accessed by first author, publication date, and key word.

Thanks to all our readers over the years who have told us how much they have enjoyed the newsletter. We hope our new quarterly publication will be equally useful in learning more about AHRQ and the field of health services research!

For questions, please contact Research Activities managing editor, Gail Makulowich, at or at 301-427-1711.

Aldosterone antagonist therapy at hospital discharge linked to modest reduced risk of rehospitalization for heart failure

Patient Safety and Quality

Among older patients experiencing heart failure and reduced ejection fraction (reduced pumping ability), using aldosterone antagonist therapy at hospital discharge was not independently associated with improved mortality or cardiovascular readmission, according to new research from AHRQ's Effective Health Care Program. However, it was associated with a modest reduction in the risk of rehospitalization for heart failure.

Though aldosterone has been shown to be effective in clinical trials, it may have limited effectiveness in real-world settings among the most vulnerable patients because of lack of adherence to or persistence with medical therapy, or inconsistent monitoring based on guideline recommendations. Strict protocols for careful monitoring and early follow-up after initiation of aldosterone antagonist therapy are needed. Additional research is also needed to evaluate the clinical effectiveness of aldosterone antagonists in the broad population of patients with heart failure and to identify strategies to overcome disparities between findings of clinical efficacy and clinical effectiveness.

See "Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction" by Adrian F. Hernandez, MD, M.H.S., Xiaojuan Mi, PhD, Bradley G. Hammill, MS, and others in the November 2012 Journal of the American Medical Association 308(20), pp. 2097-2107.

Page last reviewed January 2013
Internet Citation: Aldosterone antagonist therapy at hospital discharge linked to modest reduced risk of rehospitalization for heart failure: Patient Safety and Quality. January 2013. Agency for Healthcare Research and Quality, Rockville, MD.


The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care